Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
Quiz|Articles|June 28, 2024
Rx Roundup: Quiz of the Week — June 28, 2024
Test your pharmacy news knowledge with our weekly quiz.
Advertisement
Did you get your fill of pharmacy news this week? Take the Rx Roundup quiz of the week and test your knowledge about the latest stories published by the Drug Topics team from June 24 to June 28.
Teva Pharmaceuticals launched the first generic of which class of diabetes medication?
Advertisement
Related to this article
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
The novel tool can be used to inform vaccine policy, monitor impact, and essentially strengthen overall surveillance.
Infectious disease readiness depends on rehearsed workflows, bidirectional public health communication, and rapid access to care.
Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.
In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
3
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
4
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
5